Business
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Fran...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine\n\n\n\n\n Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models\n \n\n\n HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a new publication in the journal\n \n Vaccine,\n \n supporting the efficacy of its biodefense vaccine candidate, ATI-1701. The manuscript, titled,\n \n\n “Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection,”\n \n\n details studies showing robust and durable protection from lethal tularemia exposure in both rat and non-human primate models.\n \n\n ATI-1701, a live attenuated strain of\n \n F. tularensis\n \n , is being developed as a first-in-class vaccine to protect against tularemia, a highly contagious and potentially fatal bacterial disease. The publication, co-authored by Dr. Carl Gelhaus, Director of Non-Clinical Research at Appili, and researchers from leading biodefense institutions in the U.S., Canada, and Sweden, highlights key findings from multiple preclinical studies.\n \n\n “This publication marks a significant milestone in the development of ATI-1701 and adds to the growing body of evidence supporting its protective potential,” said Dr. Carl Gelhaus. “In both rats and cynomolgus macaques, ATI-1701 showed strong immunity against aerosolized\n \n F. tularensis\n \n SCHU S4 — one of the most virulent strains and most concerning routes of exposure. Protection was dose-dependent, long-lasting, and associated with robust immune responses, including strong antigen-specific antibody titers.”\n \n\n Key results from the study include:\n \n\n\n 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD\n \n 50\n \n ).\n \n\n In cynomolgus macaques, ATI-1701 demonstrated up to 100% protection, reduced disease severi...